Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective study of phentermine and topiramate in a United States claims database

Trial Profile

Retrospective study of phentermine and topiramate in a United States claims database

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Phentermine (Primary) ; Phentermine/topiramate (Primary) ; Topiramate (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jan 2019 According to a VIVUS media release, the company plans to include the findings from this study in the ongoing discussions with the U.S. Food and Drug Administration related to the requested label modification for Qsymia. The requested modification would allow for the safe and effective short-term use of Qsymia and could potentially reduce or modify the need for a cardiovascular outcomes study.
    • 14 Jan 2019 According to a VIVUS media release, new findings from this study will be published in the February 1, 2019 issue of The Journal of Clinical Endocrinology & Metabolism and are currently available online.
    • 12 Sep 2018 Results published in the Journal of Clinical Endocrinology and Metabolism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top